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(29%) (25 diffuse proliferative and 3 diffuse intrastent) and total
occlusions in 21 lesions (21%).
Traditionally, the presence of a focal ISR represents a rather
benign type of ISR (5). Mehran et al. (4) showed that diffuse
intrastent, proliferative, and totally occluded ISR make up a
spectrum of increasing disease severity (exaggerated neointimal
response). In our study, in contrast to data regarding sirolimus-
eluting stents in unselected lesions (6,7), the pattern of ISR after
PES implantation was non-focal in 50% of the cases. Whether this
finding represents a more exaggerated neointimal response to PES
remains to be seen in the ongoing and the upcoming randomized
trials between the two types of drug-eluting stents currently
available in the market. It is worth noting that in TAXUS IV the
pattern of restenosis in 16 lesions with ISR was predominantly
focal (62%), but still a considerable percentage (38%) of ISR
lesions were non-focal (1). Our study population, compared with
TAXUS IV patients, consisted of patients with similar rates of
diabetes (26% vs. 24%). However, the mean reference vessel
diameter was smaller (2.60 mm vs. 2.75 mm) and the mean lesion
length was longer (14.10 mm vs. 13.10 mm). In addition, a greater
number of stents per lesion were used in our study (1.23 vs. 1.08).
Similar to previous reports with sirolimus-eluting stents, ISR
occurred more frequently in the proximal than in the distal stent
border (6,7). This finding, which has been attributed to more
effective drug effect in the outflow stent border and a possible
“wash-out” of the drug, remains to be clarified (7).
The current study presents several limitations. First, this was a
retrospective analysis with the inherent caveat of the abscence of a
control group. Offsetting this limitation, the data were collected
prospectively by independent monitors and entered into a dedi-
cated database, and an independent core laboratory interpreted all
angiographic studies. Angiographic follow-up was available in 59%
of the patients and in 35% of patients was clinically driven, thereby
precluding a homogeneous evaluation of the total restenosis rate
for the global treated population. However, the patterns of
restenosis were similar between patients that had clinically driven
angiography and patients that had systematic elective control
angiography. More specifically, out of the 36 ISR lesions in the 28
patients that underwent clinically driven coronary angiogram, 18
(50%) were non-focal; of the 63 lesions in the remaining 53
patients that underwent elective control angiogram, 31 (45%) were
non-focal (p  0.9).
In conclusion, restenosis after PES implantation appears in 50%
of patients with a non-focal pattern and in the majority of the cases
involves the stent edges and more frequently the proximal than the
distal border. Diffuse proliferative ISR and ISR with total occlu-
sions are the predominant patterns when non-focal ISR occurs.
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Letters to the Editor
Rescue Angioplasty—The MERLIN Trial
Some of the issues raised by Drs. Grines and O’Neill in their
editorial in JACC (1) accompanying the Middlesbrough Early
Revascularization to Limit Infarction (MERLIN) trial report (2)
should be addressed.
Before the trial initiation, we estimated 18% mortality in the
conservative group and 6% in the rescue group, as described in the
statistical methods section. This may have been optimistic, but was
based upon a careful literature search. Power calculations cannot be
Figure 1. Schematic representation of the patterns of in-stent restenosis
(ISR) after paclitaxel-eluting stent implantation.
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made on the basis of data that subsequently become available. In
the discussion, we describe a 2% to 12% 30-day or hospital
mortality among patients undergoing rescue angioplasty, but it is
clear from the reference section that this includes data from studies
published after initiation of the MERLIN trial.
It is extraordinary for the authors to suggest that we made the
comment that 3,000 patients would be needed to show mortality
benefit and that, knowing this, we went on to perform a trial on
300 patients. First, this comment does not actually appear in our
study, having been removed (not at our request) during the review
and editing process. Second, the figure of 3,000 is an estimation of
the number required in each of the two arms in order to
demonstrate significant reduction in coronary mortality at the levels
we observed (11% conservative vs. 8.5% rescue). Their comments
imply that the authors have not understood our power calculation
and also that they have either reviewed our original study and been
subsequently unaware of changes made by the editorial team, or
been given the wrong draft to comment on in the editorial process.
We have not stated that the primary end point in the MERLIN
trial is negative, but instead that we failed to demonstrate mortality
benefit. Presentation of the results in open forum suggests that
those in favor of rescue angioplasty have seen a slight benefit in
mortality, as well as the perceived advantages of the combined end
point, and interpret this as a reason to continue a rescue program.
Conversely, skeptics interpret our results as confirming their belief
that rescue angioplasty is performed too late to be beneficial.
We agree that the majority (56%) of our patients had nonant-
erior infarction, but this is not the same as inferior infarction and
does not imply anything about infarct size. The investigators state
that randomized trials and American Heart Association/American
College of Cardiology guidelines suggest that clinical benefit from
rescue angioplasty is confined to anterior myocardial infarction
(MI). However, this is based almost entirely on data from the
RESCUE trial (3), with its limitations as described. No random-
ized trial has demonstrated lack of benefit from rescue angioplasty
in patients with nonanterior MI.
Despite the above comments, we suspect there is no major
conflict. A successful rescue angioplasty frequently benefits the
patient: the vessel opens, flow is restored, the ST segments come
down, and there are no complications. However, it is an omission
to make no comment on the potential for harm. The challenge is
to identify those patients with most to gain and the lowest risk of
harm.
We have not abandoned rescue angioplasty, and certainly not
abandoned the open-artery hypothesis. We believe that primary
angioplasty is the best treatment for ST-segment elevation myo-
cardial infarction. However, while patients continue to receive
fibrinolytics for ST-segment elevation myocardial infarction, the
question of rescue remains. Our approach is a selective one, in line
with the editorial view. Our current focus is on how to deliver
primary angioplasty to a large population in the northeast of
England with equitable access to care for all patients. If this can be
achieved, the unanswered dilemmas of rescue angioplasty will
become relatively less important.
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REPLY
We thank Drs. Sutton and Belder for their interest in our paper (1)
and again wish to compliment Sutton et al. (2) on undertaking the
largest rescue angioplasty trial conducted to date. It appears that
we were using an earlier version of the study when commenting on
the required sample size of 3,000 patients, and for this we
apologize. But all parties agree that one could not expect a
significant reduction in mortality given the small sample size and
control group mortality of only 11%.
Although we can debate whether nonanterior myocardial in-
farction (MI) is the same as inferior MI, it is clear that patients
who present with inferior ST-segment elevation have a smaller
infarct size (3) and better prognosis than patients with anterior MI
(4). Moreover, given the low baseline risk of inferior MI patients,
it has been difficult to prove a mortality advantage with reperfusion
therapy compared to placebo (4).
So what have we learned from the MERLIN trial? It is clear
that rescue angioplasty has room for improvement. Consistently,
rates of Thrombolysis In Myocardial Infarction (TIMI) flow grade
3 after rescue percutaneous coronary intervention (PCI) are lower
than those reported after primary PCI. We had hoped that
extraction of thrombosis or use of distal protection devices would
improve perfusion and clinical outcomes. Yet large, randomized
trials using distal protection (EMERALD trial) or thrombectomy
(AIMI trial) showed no improvement in TIMI flow grades,
myocardial blush scores, infarct size, or major adverse cardiac
events compared to PCI alone (5). The lack of benefit may have
been due to embolization with saline agitation, advancing the
device past the thrombotic lesion or diverting emboli into proximal
side branches. Therefore, it is possible that use of lower-profile
thrombectomy catheters, filters, or proximal protection devices
may be of benefit.
We agree with the MERLIN investigators that the focus should
not be on rescue PCI, but on how to deliver primary angioplasty to
a larger population. Performance of primary PCI (by an experi-
enced PCI operator) in a diagnostic-only catheterization labora-
tory would increase availability enormously. We should work
toward a goal of performing prehospital electrocardiography and
transferring patients with ST-segment elevation myocardial infarc-
tion from home, directly to a primary PCI center.
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